Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 8/2017

01-08-2017 | Original Article

Surveillance of anal carcinoma after radiochemotherapy

A retrospective analysis of 80 patients

Authors: Dr. med. Matthias Sauter, MD, Prof. Dr. Stephan R. Vavricka, MD, med. pract. Georg Keilholz, Henriette Heinrich, PD Dr. Thomas Winder, MD PhD, Helmut Kranzbühler, MD, Norbert Lombriser, MD, PD Dr. Benjamin Misselwitz, MD

Published in: Strahlentherapie und Onkologie | Issue 8/2017

Login to get access

Abstract

Background

Surveillance after radiochemotherapy of anal carcinoma (ACa) with curative intent is recommended in guidelines, but data regarding the effectiveness of follow-up are lacking. We aimed to assess the performance of an ACa surveillance program in a real-life setting.

Methods

We retrospectively summarized clinical history, physical findings, and follow-up investigations (endoanal ultrasound, endoscopy, CT scan) obtained during 42 months (±27 months) from 80 patients after radiochemotherapy of ACa.

Results

In 7/80 cases (8.8%) an incomplete response to therapy was identified at or before the 6‑month time point after the end of treatment; 4 of the 7 cases were identified during scheduled follow-up. In 6 cases (7.5%), recurrent disease was found after the 6‑month time point. Recurrence was systemic in 5 cases and local/inguinal in 1 case. In 3 of the 6 cases (50%), recurrence was identified during scheduled follow-up. In one asymptomatic patient, a single liver metastasis was detected during scheduled follow-up and the patient remains free of disease 19 months after surgery. Surveillance resulted in a high rate of false-positive findings (70 findings in 604 investigations), of which only 14 could be confirmed.

Conclusion

Scheduled follow-up after treatment of ACa detected recurrent disease at systemic sites, enabling potentially curative treatment in a single case. Effectiveness of abdominal imaging during follow-up after ACa treatment should be tested in a prospective trial.
Appendix
Available only for authorised users
Literature
1.
Allemani C, Weir HK, Carreira H et al (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972):977–1010CrossRefPubMed
2.
Mitry E, Bouvier AM, Esteve J, Faivre J (2005) Improvement in colorectal cancer survival: a population-based study. Eur J Cancer 41(15):2297–2303CrossRefPubMed
3.
Fraunholz I, Rabeneck D, Weiss C, Rodel C (2010) Combined-modality treatment for anal cancer: current strategies and future directions. Strahlenther Onkol 186(7):361–366CrossRefPubMed
4.
Glynne-Jones R, Nilsson PJ, Aschele C et al (2014) Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii10–iii20CrossRefPubMed
5.
James RD, Glynne-Jones R, Meadows HM et al (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol 14(6):516–524CrossRefPubMed
6.
Nigro ND, Vaitkevicius VK, Considine B Jr. (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17(3):354–356CrossRefPubMed
7.
Osborne MC, Maykel J, Johnson EK, Steele SR (2014) Anal squamous cell carcinoma: an evolution in disease and management. World J Gastroenterol 20(36):13052–13059CrossRefPubMedPubMedCentral
8.
Tanum G, Tveit K, Karlsen KO, Hauer-Jensen M (1991) Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 67(10):2462–2466CrossRefPubMed
9.
Fakhrian K, Sauer T, Klemm S et al (2013) Radiotherapy with or without chemotherapy in the treatment of anal cancer: 20-year experience from a single institute. Strahlenther Onkol 189(1):18–25CrossRefPubMed
10.
Fakhrian K, Sauer T, Dinkel A et al (2013) Chronic adverse events and quality of life after radiochemotherapy in anal cancer patients. A single institution experience and review of the literature. Strahlenther Onkol 189(6):486–494CrossRefPubMed
11.
Welzel G, Hagele V, Wenz F, Mai SK (2011) Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. Strahlenther Onkol 187(3):175–182CrossRefPubMed
12.
13.
Eberhardt WE, De Ruysscher D, Weder W et al (2015) 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 26(8):1573–1588CrossRefPubMed
14.
Oberg K, Akerstrom G, Rindi G, Jelic S (2010) Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v223–v227CrossRefPubMed
15.
Renehan AG, Egger M, Saunders MP, O’Dwyer ST (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324(7341):813CrossRefPubMedPubMedCentral
16.
Rosen M, Chan L, Beart RW Jr. et al (1998) Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 41(9):1116–1126CrossRefPubMed
17.
Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50(11):1783–1799CrossRefPubMed
18.
Ducreux M, Cuhna AS, Caramella C et al (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–68CrossRefPubMed
19.
Stahl M, Mariette C, Haustermans K et al (2013) Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi51–vi56CrossRefPubMed
20.
Jemal A, Simard EP, Dorell C et al (2013) Annual Report to the Nation on the Status of Cancer, 1975–2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105(3):175–201CrossRefPubMedPubMedCentral
21.
Johnson LG, Madeleine MM, Newcomer LM et al (2004) Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973–2000. Cancer 101(2):281–288CrossRefPubMed
22.
23.
Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62(2):118–128CrossRefPubMed
24.
25.
Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14(9):2527–2539CrossRefPubMed
26.
Glynne-Jones R, Sebag-Montefiore D, Meadows HM et al (2017) Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol 18(3):347–356CrossRefPubMedPubMedCentral
27.
Sauter M, Keilholz G, Kranzbuhler H et al (2016) Presenting symptoms predict local staging of anal cancer: a retrospective analysis of 86 patients. BMC Gastroenterol 16:46CrossRefPubMedPubMedCentral
28.
Edge SB, Compton CC (eds) (2010) AJCC Cancer Staging Handbook, 7th edn. Springer, New York
29.
Hellman S (1994) Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 12(10):2229–2234CrossRefPubMed
30.
31.
Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8(6):378–382PubMed
32.
Lo SS, Moffatt-Bruce SD, Dawson LA et al (2011) The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 8(7):405–416CrossRefPubMed
33.
34.
Pienta KJ, Robertson BA, Coffey DS, Taichman RS (2013) The cancer diaspora: Metastasis beyond the seed and soil hypothesis. Clin Cancer Res 19(21):5849–5855CrossRefPubMed
35.
Hu C, Chang EL, Hassenbusch SJ 3rd et al (2006) Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 106(9):1998–2004CrossRefPubMed
36.
Jones RP, Stattner S, Sutton P et al (2014) Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surg Oncol 23(2):53–60CrossRefPubMed
37.
Pawlik TM, Gleisner AL, Bauer TW et al (2007) Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol 14(10):2807–2816CrossRefPubMed
38.
Gryc T, Ott O, Putz F et al (2016) Interstitial brachytherapy as a boost to patients with anal carcinoma and poor response to chemoradiation: Single-institution long-term results. Brachytherapy 15(6):865–872CrossRefPubMed
39.
Peiffert D, Tournier-Rangeard L, Gerard JP et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30(16):1941–1948CrossRefPubMed
Metadata
Title
Surveillance of anal carcinoma after radiochemotherapy
A retrospective analysis of 80 patients
Authors
Dr. med. Matthias Sauter, MD
Prof. Dr. Stephan R. Vavricka, MD
med. pract. Georg Keilholz
Henriette Heinrich
PD Dr. Thomas Winder, MD PhD
Helmut Kranzbühler, MD
Norbert Lombriser, MD
PD Dr. Benjamin Misselwitz, MD
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 8/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1159-0

Other articles of this Issue 8/2017

Strahlentherapie und Onkologie 8/2017 Go to the issue

Case Study

Successful treatment of a rare case of ameloblastic fibrosarcoma with radiation therapy

Editorial

Personalized radiotherapy for invasive breast cancer in 2017

Original Article

Automation of radiation treatment planning

Literatur kommentiert

30-Tage-Letalität nach systemischer Chemotherapie

Original Article

External-beam radiation therapy combined with limb-sparing surgery in elderly patients (>70 years) with primary soft tissue sarcomas of the extremities

Erratum

Erratum to: Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters